CytoDyn Inc. (OTCMKTS:CYDY – Get Free Report)’s share price was down 4% on Monday . The company traded as low as $0.14 and last traded at $0.14. Approximately 2,274,842 shares changed hands during trading, a decline of 11% from the average daily volume of 2,542,370 shares. The stock had previously closed at $0.15.
CytoDyn Price Performance
The company has a market cap of $142.52 million, a P/E ratio of -2.81 and a beta of 0.13. The stock’s 50-day moving average is $0.15 and its two-hundred day moving average is $0.15.
CytoDyn (OTCMKTS:CYDY – Get Free Report) last released its quarterly earnings results on Tuesday, October 15th. The biotechnology company reported $0.02 earnings per share for the quarter.
CytoDyn Company Profile
CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.
Read More
- Five stocks we like better than CytoDyn
- What are earnings reports?
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- What is the Euro STOXX 50 Index?
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- What Does a Stock Split Mean?
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
